ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: SA-PO484

Significantly Less CMV- and BKV-Events with Everolimus-Based versus Tacrolimus-MPA Regimen in De Novo Renal Transplant Recipients: 12 Months Data on Infections from the Athena Study

Session Information

Category: Transplantation

  • 1702 Transplantation: Clinical and Translational


  • Hauser, Ingeborg Anni, University Clinic Frankfurt (UKF), Frankfurt Main, Germany
  • Sommerer, Claudia, University Hospital of Heidelberg, HEIDELBERG, Germany
  • Suwelack, Barbara M., None, Muenster, Germany
  • Dragun, Duska, University Hospital Charite, Campus Virchow, Berlin, Germany
  • Schenker, Peter, Ruhr-University Bochum, Bochum, Germany
  • Witzke, Oliver, University Duisburg-Essen, Essen, Germany
  • Hugo, Christian, University of Dresden, Dresden, Germany, Dresden, SN, Germany
  • Kamar, Nassim, Toulouse University Hospital, Toulouse, France
  • Merville, Pierre, PELLEGRIN HOSPITAL, Bordeaux, France
  • Junge, Martina, Novartis Pharma GmbH Germany, Nuremberg, Germany
  • Thaiss, Friedrich, University Hospital, Hamburg, Germany
  • Nashan, Björn, Bundesärztekammer , Hamburg, Germany

Group or Team Name

  • Athena Study Group

The ATHENA trial was designed to compare everolimus [EVR] in combination with tacrolimus [TAC] or cyclosporine A [CyA] vs. a standard of mycophenolic acid [MPA] and TAC in de novo kidney transplant [KTx] recipients.


In this 12 months [M], prospective, open-label, randomized study with 15 German and 12 French sites, 612 patients [pts] were randomized 1:1:1 at time of Tx to either EVR (3-8ng/ml M1-M12) +TAC (4-8ng/ml M1-M3; 3-5ng/ml M3-M12), or EVR (3-8ng/ml M1-M12) + CyA (75-125ng/ml M1-M3; 50-100ng/ml M3-M12) or to control TAC regimen (4-8ng/ml M1-M3; 3-5ng/ml M3-M12) with MPA. All pts continued on steroids. Herein we report M12 outcomes on infections and CMV events from ITT with 208 EVR+TAC pts, 199 EVR+CyA pts and 205 TAC+MPA pts.


From randomization to M12 total incidences of infections were 73% in EVR+TAC and 72% in EVR+CyA treated pts vs 82% in TAC+MPA pts. Whilst incidences of bacterial infections were similar between the three treatment groups (44% EVR+TAC, 43% EVR+CyA, 42% TAC+MPA) major differences were seen for viral infections with incidences of 41% in TAC+MPA vs only 26% in EVR+TAC and 12% in EVR+CyA groups. Incidence of BKV events was 23% in TAC+MPA vs 17% in EVR+TAC vs 9% in EVR+CyA pts (p<0.01). CMV events occurred two thirds less in EVR treated pts compared to TAC+MPA control group with an incidence of 21% in TAC+MPA vs 6% for EVR+TAC and 3% for EVR+CyA treatment pts (p<0.001).


ATHENA as largest European KTx study confirmed comparable efficacy and safety together with less viral infections for EVR-based treatment groups compared to TAC+MPA group. A significant, protective effect of EVR-based regimens vs CMV/BKV events was robustly confirmed.


  • Commercial Support –